Should Beta-Blocker Be Started in HFmrEF with HR 69?
Yes, beta-blocker therapy should be started in this patient with heart failure with mildly reduced ejection fraction (HFmrEF), as the evidence supports mortality and morbidity benefits in this population, and a heart rate of 69 bpm is not a contraindication.
Rationale for Beta-Blocker Initiation
The 2022 AHA/ACC/HFSA guidelines provide a Class 2b recommendation for beta-blockers in HFmrEF 1, which represents a weaker recommendation than for HFrEF but still supports their use. While this is not as strong as the Class 1 recommendation for HFrEF (EF ≤40%), the evidence base demonstrates meaningful benefits.
Evidence Supporting Beta-Blocker Use in HFmrEF
The most compelling recent evidence comes from an individual patient-level meta-analysis of 11 double-blind randomized trials 2. For patients with LVEF 40-49%, beta-blockers reduced:
- All-cause mortality: 7.2% vs 12.4% with placebo (adjusted HR 0.59,95% CI 0.34-1.03)
- Cardiovascular death: 4.5% vs 9.2% with placebo (adjusted HR 0.48,95% CI 0.24-0.97)
This represents approximately a 40% reduction in mortality risk, which is clinically meaningful even if the confidence interval crosses 1.0 for all-cause mortality.
A 2023 real-world analysis from the PINNACLE Registry 3 involving 75,674 patients with HFmrEF showed that beta-blockers were associated with decreased risk of both HF hospitalization and death in HFmrEF patients. Importantly, this benefit diminished as EF increased above 50%, with potential harm when EF exceeded 60%.
Heart Rate Considerations
Your patient's heart rate of 69 bpm is NOT a contraindication to beta-blocker initiation. The guidelines specify that symptomatic bradycardia is a contraindication 4, not a specific heart rate threshold.
Key points about heart rate:
- Beta-blockers typically reduce heart rate by approximately 12 beats/min 5
- The benefit of beta-blockers in patients with sinus rhythm occurs regardless of baseline heart rate (interaction p = 0.35) 5
- Bradycardia becomes a concern only when symptomatic or when it requires discontinuation of rate-lowering medications 4
Practical Implementation
Follow this stepwise approach 4, 6:
- Ensure patient stability: Patient should be relatively stable without marked fluid retention or need for IV inotropes
- Confirm background therapy: Patient should be on ACE inhibitor/ARB/ARNI unless contraindicated
- Start low, go slow: Use evidence-based beta-blockers only:
- Bisoprolol: Start 1.25 mg daily, target 10 mg daily
- Carvedilol: Start 3.125 mg twice daily, target 25-50 mg twice daily
- Metoprolol succinate (extended-release): Start 12.5-25 mg daily, target 200 mg daily
- Titration schedule: Double dose every 1-2 weeks if tolerated 4, 6
- Monitoring: Check blood pressure and heart rate at each titration; assess for worsening symptoms
Common Pitfalls to Avoid
- Don't use non-evidence-based beta-blockers: Only bisoprolol, carvedilol, and metoprolol succinate have proven mortality benefit 6, 7
- Don't withhold due to asymptomatic bradycardia: A resting HR of 69 is acceptable for initiation
- Don't stop abruptly if side effects occur: First optimize diuretics or reduce vasodilators; temporarily reduce beta-blocker dose if necessary, but always attempt reintroduction 4
- Don't delay initiation: The survival benefit includes reduction in sudden death 7, so treatment should not be postponed in stable patients
Contraindications to Check
Absolute contraindications 4:
- Asthma bronchiale or severe bronchial disease
- Symptomatic bradycardia or hypotension (not just numbers)
- Decompensated heart failure requiring IV inotropes
Relative contraindications requiring specialist referral 4:
- Severe heart failure (NYHA Class III/IV)
- Previous beta-blocker discontinuation due to symptoms
- Intolerance to low doses
Special Considerations for HFmrEF
HFmrEF represents a transitional phenotype—many patients either improved from lower EF or deteriorated from higher EF 8. Continue beta-blocker therapy even if EF improves above 40% 1, as these patients benefit from ongoing neurohormonal blockade. The evidence suggests beta-blockers provide the most robust benefit when EF is below 50% 3, making your patient with mildly reduced EF an ideal candidate.
The 2020 ACC/AHA performance measures emphasize that beta-blocker therapy should be prescribed to all eligible patients with current or prior LVEF ≤40% 6, and the evidence extends this benefit into the 40-49% range 2.